188 related articles for article (PubMed ID: 28584186)
1. Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data.
Singh JA; Cleveland JD
Ann Rheum Dis; 2017 Oct; 76(10):1669-1678. PubMed ID: 28584186
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults: a propensity-matched analysis.
Singh JA; Cleveland JD
Arthritis Res Ther; 2018 Aug; 20(1):167. PubMed ID: 30075731
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data.
Singh JA; Cleveland JD
Eur Heart J; 2019 Sep; 40(36):3046-3054. PubMed ID: 30919894
[TBL] [Abstract][Full Text] [Related]
4. Are allopurinol dose and duration of use nephroprotective in the elderly? A Medicare claims study of allopurinol use and incident renal failure.
Singh JA; Yu S
Ann Rheum Dis; 2017 Jan; 76(1):133-139. PubMed ID: 27296322
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
Singh JA; Akhras KS; Shiozawa A
Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
[TBL] [Abstract][Full Text] [Related]
6. Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data.
Singh JA; Cleveland JD
Ann Rheum Dis; 2020 Apr; 79(4):529-535. PubMed ID: 32024648
[TBL] [Abstract][Full Text] [Related]
7. Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
Mitri G; Wittbrodt ET; Turpin RS; Tidwell BA; Schulman KL
J Manag Care Spec Pharm; 2016 Apr; 22(4):326-36. PubMed ID: 27023686
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.
Zhang M; Solomon DH; Desai RJ; Kang EH; Liu J; Neogi T; Kim SC
Circulation; 2018 Sep; 138(11):1116-1126. PubMed ID: 29899013
[TBL] [Abstract][Full Text] [Related]
9. Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study.
Kang EH; Choi HK; Shin A; Lee YJ; Lee EB; Song YW; Kim SC
Rheumatology (Oxford); 2019 Dec; 58(12):2122-2129. PubMed ID: 31098635
[TBL] [Abstract][Full Text] [Related]
10. Allopurinol and the risk of atrial fibrillation in the elderly: a study using Medicare data.
Singh JA; Yu S
Ann Rheum Dis; 2017 Jan; 76(1):72-78. PubMed ID: 27165177
[TBL] [Abstract][Full Text] [Related]
11. Gout and chronic pain in older adults: a Medicare claims study.
Singh JA; Cleveland JD
Clin Rheumatol; 2019 Jul; 38(7):1953-1960. PubMed ID: 30927116
[TBL] [Abstract][Full Text] [Related]
12. A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study
.
Zhou Q; Su J; Zhou T; Tian J; Chen X; Zhu J
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):163-168. PubMed ID: 27936522
[TBL] [Abstract][Full Text] [Related]
13. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC
Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805
[TBL] [Abstract][Full Text] [Related]
14. Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study.
Su CY; Shen LJ; Hsieh SC; Lin LY; Lin FJ
Mayo Clin Proc; 2019 Jul; 94(7):1147-1157. PubMed ID: 31272565
[TBL] [Abstract][Full Text] [Related]
15. The association of gout with incident giant cell arteritis in older adults.
Singh JA; Cleveland JD
Joint Bone Spine; 2019 Mar; 86(2):219-224. PubMed ID: 29885976
[TBL] [Abstract][Full Text] [Related]
16. A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database.
Altan A; Shiozawa A; Bancroft T; Singh JA
J Clin Rheumatol; 2015 Dec; 21(8):411-8. PubMed ID: 26580304
[TBL] [Abstract][Full Text] [Related]
17. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
Chou HW; Chiu HT; Tsai CW; Ting IW; Yeh HC; Huang HC; Kuo CC;
Nephrol Dial Transplant; 2018 Sep; 33(9):1620-1627. PubMed ID: 29165620
[TBL] [Abstract][Full Text] [Related]
19. Febuxostat in the management of gout: a cost-effectiveness analysis.
Smolen LJ; Gahn JC; Mitri G; Shiozawa A
J Med Econ; 2016; 19(3):265-76. PubMed ID: 26535593
[TBL] [Abstract][Full Text] [Related]
20. Gout and dementia in the elderly: a cohort study of Medicare claims.
Singh JA; Cleveland JD
BMC Geriatr; 2018 Nov; 18(1):281. PubMed ID: 30428833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]